Department of Urology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
Urol Clin North Am. 2012 May;39(2):171-9, vi. doi: 10.1016/j.ucl.2012.01.003. Epub 2012 Feb 21.
Accurately conveying the benefits and risks of treatment interventions to patients diagnosed with small renal masses (SRMs) is essential to appropriately identify which patients will achieve better oncologic outcomes and confer a survival advantage from primary therapy. Treatment decisions to determine the ideal management with nephrectomy, thermal ablation, or active surveillance for patients diagnosed with an SRM remain highly complex. Existing prediction tools that incorporate various key clinical variables may facilitate an informed decision about the best management of SRM by more appropriately selecting treatment individualized to the characteristics of the SRM and the patient's clinical characteristics.
准确向诊断为小肾肿瘤 (SRM) 的患者传达治疗干预的获益和风险,对于正确识别哪些患者将获得更好的肿瘤学结果并从初始治疗中获得生存优势至关重要。对于诊断为 SRM 的患者,确定采用肾切除术、热消融或主动监测进行理想管理的治疗决策仍然非常复杂。现有的预测工具结合了各种关键临床变量,通过更恰当地选择针对 SRM 特征和患者临床特征的个体化治疗,可能有助于做出关于 SRM 最佳管理的知情决策。